delamanid   Click here for help

GtoPdb Ligand ID: 12876

Synonyms: Deltyba® | OPC-67683
Approved drug
delamanid is an approved drug (EMA (2014))
Compound class: Synthetic organic
Comment: Delamanid is a nitro-dihydro-imidazooxazole derivative with potent antibacterial activity against mycobacteria [1-2]. This drug is used in the treatment of multidrug-resistant tuberculosis (MDR-TB).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 9
Topological polar surface area 98.9
Molecular weight 534.49
XLogP 5.67
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
Isomeric SMILES C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
InChI InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
InChI Key XDAOLTSRNUSPPH-XMMPIXPASA-N
No information available.
Summary of Clinical Use Click here for help
Delamanid is indicated for the treatment of pulmonary MDR-TB and is administered in conjunction with other tuberculosis medicines. It is on the World Health Organization's Model List of Essential Medicines and was given conditional authorisation by the EMA in 2014.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Delamanid inhibits the biosynthesis of mycolic acid, an essential component of the cell wall of M. tuberculosis (IC50 of 0.021-0.036 μg/ml) [1].
External links Click here for help
For extended ADME data see the following:

European Medicines Agency (EMA)